Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,187.70 +6.96 (+0.13%) Dow
38,884.26 +31.99 (+0.08%) Nasdaq
16,332.56 -16.69 (-0.10%) Bitcoin USD
62,310.40 -1,842.77 (-2.87%) CMC Crypto 200
1,287.70 -6.97 (-0.54%)
MCK Jan 2025 440.000 call
| Previous close | 121.00 |
| Open | 121.00 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 440.00 |
| Expiry date | 2025-01-17 |
| Day's range | 121.00 - 121.00 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- GuruFocus.com
McKesson Corp (MCK) Q4 2024 Earnings Call Transcript Highlights: Strong Growth and Strategic ...
Discover how McKesson's strategic initiatives and robust financial performance are shaping its industry leadership in Q4 2024.
- Reuters
McKesson misses quarterly estimates as US pharmaceuticals segment weighs
McKesson Corp reported weaker-than-expected quarterly revenue and profit on Tuesday due to slump in demand for the company's branded and specialty drugs that dragged sales in its U.S. pharmaceutical segment. The segment also sells branded and generic drugs, as well as over-the-counter products and vaccines. Sales in the segment rose 11.5% in the fourth quarter to $68.79 billion, but missed analysts' estimate of $71.65 billion, according to LSEG data.
ZacksMcKesson (MCK) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
